References
- NAINGGOLAN L: Obesity is the worst chronic health problem. Script (1997) 2244:25.
- ARONNE LJ: Obesity. Med. Clin. N Am. (1998) 82:161–181.
- ROSENBAUM M, LEIBEL RL, HIRSCH J: Obesity. N Engl. I Med. (1997) 337:396–407.
- VANTALLIE TB: Worldwide epidemiology of obesity. Pharmacoeconomics (1994) 5\(Suppl. 1):1–7.
- SEIDELL JC, DEERENBERG I: Obesity in Europe: prevalence and consequence for use of medical care. Pharmacoeconomics (1994) 5\(Suppl. 1):38–44.
- RAVUSSIN E: Energy metabolism in obesity: study in Pima Indians. Diabetes Care (1993) 16:232–238.
- WOLF AM, COLDITZ GA: Current estimates of the economic cost of obesity in the United States. Obes. Res. (1998) 6:97–106.
- The prevention and treatment of obesity. Eff Health Care (1997) 3:1–12.
- The North American Association for the Study of Obesity: Guidelines the approval and use of drugs to treat obesity. Obes. Res. (1995) 3:473–478.
- GUY-GRAND B: Pharmacological approaches to intervention. Int. J. Obes. (1997) 21\(Suppl. 1):522–524.
- ANON: British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. (2000):40.
- Withdrawal of dexfenflummine (Adifax) and fenflummine (Ponderaid: concerns about the effect on heart valves Servier Laboratories Ltd, France (1997).
- Xenical. Summary of product characteristics. Roche Ltd (2000).
- SOJOSTROM L, RISANEN A, ANDERSEN T et al: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet (1998) 352:167–172.
- DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA (1999) 281:235–242.
- HOLLANDER PA, ELBEIN SC, HIRSCH IB et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care (1998) 21:1288–1294.
- MCDUFFIE JR, CALIS KA,UWAIFO GI et al.: Three month tolerability of orlistat in adolescents with obesity related comorbid conditions. Obes. Res. (2002) 10:642–650.
- MCNELLY W, GOA KL: Sibutramine inobesity: a review. Drugs (1998) 56:1093–1124.
- GARATT CJ, HIND ID, HADDOCK RE: Sibutramine metabolite kinetics in young and elderly subjects. Clin. Pharmacol. (1994) 35:928.
- KAISER PE, HINSON JL: Sibutramine dose response and plasma metabolite concentration in weight loss.' Clin. Pharmacol (1994) 34:1019.
- JOHNSON F, VELAGAPUDI R, HIND I et al.: Effects of renal dysfuction on the pharmacokinetics of sibutramine and its metabolites.' Clin. Prarmacol. (1997) 37:865.
- PHILIP W, JAMES T, ASTRUP A et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet (2000) 356:2119–2125.
- BRAY GA, RYAN DH, GORDON D et al.: Double blind randomised placebo-controlled trial of sibutramine. Obes. Res. (1996) 4:263–270.
- KELLY F, WADE AG, JONES SP et al.: Sibutramine hydrochloride versus dexfenfluramine: weight loss in obese subjects. Int. J. Obes. (1995) 18(Suppl.):61.
- APFELBAUM M, VAGUE P, ZEIGLER 0 et al.: Long term maintenance pf weight loss after a very-low calorie diet: efficacy and tolerability of sibutramine versus placebo. Am. .1. Med. (In press).
- FUJIOKA K, SEATON TB, ROWE E, et al.: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. (2000) 2:175–187.